TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.

The following ratings changes were generated on Friday, June 5.

We've upgraded AmerisourceBergen ( ABC) from hold to buy, driven by its growth in earnings per share, increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins.

Earnings per share improved by 17.3% in the most recent quarter compared with the same quarter last year, and we feel that the company's two-year trend of EPS growth should continue. Net income increased by 7.1% compared with the year-ago quarter, from $133.9 million to $143.4 million. Net operating cash flow increased by 74.2% to $336.8 million, exceeding the industry average cash flow growth rate of 53.4%. AmerisourceBergen's debt-to-equity ratio of 0.4 is below the industry average, though the quick ratio of 0.5 implies a potential problem covering short-term cash needs. Return on equity improved compared with the year-ago quarter.

We've downgraded Gushan Environmental Energy ( GU) from hold to sell, driven by its unimpressive growth in net income, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Net income fell to -$340,000 from $15.9 million compared with the year-ago quarter. Gushan's gross profit margin of 19% has decreased significantly from the year-ago quarter, and net profit margin of -0.8% trails the industry average. EPS declined from the year-ago quarter, and we fell the company is likely to report a decline in earnings in the coming year. Revenue fell by 15.9% since the year-ago quarter.

If you liked this article you might like

How You Can Beat the Still Astronomical Prices for Prescription Drugs

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Walgreens Takes Piece of PharMerica, Quest to Dominate Healthcare Continues